Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group
Oliver Schnell, Eberhard Standl, Doina Catrinoiu, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Diabetes and Covid-19 among hospitalized patients in Saudi Arabia: a single-centre retrospective study
Abdullah Alguwaihes, Mohammed E. Al‐Sofiani, Maram Megdad, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 147
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell, Katharine Barnard‐Kelly, Tadej Battelino, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
Francesco Prattichizzo, Lucia La Sala, Lars Rydén, et al.
European Journal of Preventive Cardiology (2019) Vol. 26, Iss. 2_suppl, pp. 73-80
Open Access | Times Cited: 66
Renal Effects of Sodium-Glucose Co-Transporter Inhibitors
Scott C. Thomson, Volker Vallon
The American Journal of Cardiology (2019) Vol. 124, pp. S28-S35
Open Access | Times Cited: 57
A Deep Learning Approach to Predict Diabetes’ Cardiovascular Complications From Administrative Claims
Enrico Longato, Gian Paolo Fadini, Giovanni Sparacino, et al.
IEEE Journal of Biomedical and Health Informatics (2021) Vol. 25, Iss. 9, pp. 3608-3617
Closed Access | Times Cited: 46
Electrical Features of the Diabetic Myocardium. Arrhythmic and Cardiovascular Safety Considerations in Diabetes
Mónica Gallego, Julián Zayas-Arrabal, Amaia Alquiza, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 36
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell, Jaime P. Almandoz, Lisa Anderson, et al.
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access
Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study
Reimar W. Thomsen, Jakob S. Knudsen, Johnny Kahlert, et al.
Journal of the American Heart Association (2021) Vol. 10, Iss. 11
Open Access | Times Cited: 24
Report from the 5th cardiovascular outcome trial (CVOT) summit
Oliver Schnell, Eberhard Standl, Xavier Cos, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 22
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
Oliver Schnell, Tadej Battelino, Richard M. Bergenstal, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer anti‐hyperglycaemic drug matters?
Dario Giugliano, Antonio Ceriello, Luca De Nicola, et al.
Diabetes Obesity and Metabolism (2019) Vol. 22, Iss. 2, pp. 149-157
Closed Access | Times Cited: 21
Two drugs are better than one to start T2DM therapy
Francesco Prattichizzo, Lucia La Sala, Antonio Ceriello
Nature Reviews Endocrinology (2019) Vol. 16, Iss. 1, pp. 15-16
Closed Access | Times Cited: 20
Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data
Maximilian Brockmeyer, Claudio Parco, Kris Gregory Vargas, et al.
Journal of Nephrology (2024) Vol. 37, Iss. 2, pp. 309-321
Open Access | Times Cited: 2
Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: A real‐world study of patients followed for up to 19 years
Briana Coles, Francesco Zaccardi, Christian Hvid, et al.
Diabetes Obesity and Metabolism (2020) Vol. 23, Iss. 1, pp. 218-227
Open Access | Times Cited: 17
Series: Implications of the recent CVOTs in type 2 diabetes
André Scheen
Diabetes Research and Clinical Practice (2019) Vol. 159, pp. 107726-107726
Closed Access | Times Cited: 17
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
Oliver Schnell, Tadej Battelino, Richard M. Bergenstal, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 9
Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
Luca De Nicola, Mario Cozzolino, Simonetta Genovesi, et al.
Journal of Nephrology (2022) Vol. 35, Iss. 6, pp. 1605-1618
Open Access | Times Cited: 9
“H” for Heterogeneity in the Algorithm for Type 2 Diabetes Management
Silvia Pieralice, Simona Zampetti, Ernesto Maddaloni, et al.
Current Diabetes Reports (2020) Vol. 20, Iss. 5
Closed Access | Times Cited: 12
Cardio‐renal‐metabolic disease in primary care setting
Mahmoud Ibrahim, Ebtesam Ba-Essa, Jason Baker, et al.
Diabetes/Metabolism Research and Reviews (2023) Vol. 40, Iss. 3
Open Access | Times Cited: 4
Report from the CVOT Summit 2020: new cardiovascular and renal outcomes
Oliver Schnell, Xavier Cos, Francesco Cosentino, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 10
Glucocentric and cardiocentric approaches to achieving type 2 diabetes compensation
V.І. Pankiv
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) (2023) Vol. 19, Iss. 5, pp. 344-348
Open Access | Times Cited: 3
Role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in diabetic complications
Omonzejie E. Imaralu, Chandrakala Aluganti Narasimhulu, Pawan K. Singal, et al.
Canadian Journal of Physiology and Pharmacology (2023) Vol. 102, Iss. 01, pp. 14-25
Closed Access | Times Cited: 3
Renal Effects of Sodium-Glucose Co-Transporter Inhibitors
Scott C. Thomson, Volker Vallon
The American Journal of Medicine (2019) Vol. 132, Iss. 10, pp. S30-S38.e4
Open Access | Times Cited: 7
Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study
Sohee Park, Han Eol Jeong, In‐Sun Oh, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 6, pp. 1232-1241
Closed Access | Times Cited: 7
Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study
Siyao He, Xin Qian, Yanyan Chen, et al.
Journal of Diabetes Research (2021) Vol. 2021, pp. 1-10
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top